These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

707 related items for PubMed ID: 27993383

  • 1. Old challenges and new opportunities in the clinical management of heterozygous familial hypercholesterolemia (HeFH): The promises of PCSK9 inhibitors.
    Arca M.
    Atherosclerosis; 2017 Jan; 256():134-145. PubMed ID: 27993383
    [Abstract] [Full Text] [Related]

  • 2. Statin intolerance in heterozygous familial hypercolesterolemia with cardiovascular disease: After PCSK-9 antibodies what else?
    Sbrana F, Dal Pino B, Bigazzi F, Ripoli A, Passino C, Gabutti A, Pasanisi EM, Petersen C, Valleggi A, Todiere G, Barison A, Giannoni A, Panchetti L, Becherini F, Pianelli M, Luciani R, Sampietro T.
    Eur J Prev Cardiol; 2017 Sep; 24(14):1528-1531. PubMed ID: 28555526
    [Abstract] [Full Text] [Related]

  • 3. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
    Yadav K, Sharma M, Ferdinand KC.
    Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
    [Abstract] [Full Text] [Related]

  • 4. Anti-PCSK9 antibodies for the treatment of heterozygous familial hypercholesterolemia: patient selection and perspectives.
    Catapano AL, Pirillo A, Norata GD.
    Vasc Health Risk Manag; 2017 Oct; 13():343-351. PubMed ID: 28919772
    [Abstract] [Full Text] [Related]

  • 5. Lipoprotein Apheresis and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Patients With Heterozygous Familial Hypercholesterolemia: A One Center Study.
    Kolovou V, Katsiki N, Makrygiannis S, Mavrogieni S, Karampetsou N, Manolis A, Melidonis A, Mikhailidis DP, Kolovou GD.
    J Cardiovasc Pharmacol Ther; 2021 Jan; 26(1):51-58. PubMed ID: 32729335
    [Abstract] [Full Text] [Related]

  • 6. Evolving trend in the management of heterozygous familial hypercholesterolemia in Italy: A retrospective, single center, observational study.
    D'Erasmo L, Commodari D, Di Costanzo A, Minicocci I, Polito L, Ceci F, Montali A, Maranghi M, Arca M.
    Nutr Metab Cardiovasc Dis; 2020 Oct 30; 30(11):2027-2035. PubMed ID: 32830020
    [Abstract] [Full Text] [Related]

  • 7. Eligibility for alirocumab or evolocumab treatment in 1090 hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥70 mg/dL despite maximal-tolerated LDL-cholesterol-lowering therapy.
    Jetty V, Glueck CJ, Lee K, Goldenberg N, Prince M, Kumar A, Goldenberg M, Anand I, Wang P.
    Vasc Health Risk Manag; 2017 Oct 30; 13():247-253. PubMed ID: 28740397
    [Abstract] [Full Text] [Related]

  • 8. PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab.
    Blom DJ, Dent R, Castro RC, Toth PP.
    Vasc Health Risk Manag; 2016 Oct 30; 12():185-97. PubMed ID: 27274264
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Eligibility for PCSK9 treatment in 734 Hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥ 70 mg/dl despite maximal tolerated cholesterol lowering therapy.
    Glueck CJ, Shah P, Goldenberg N, Prince M, Lee K, Jetty V, Kumar A, Goldenberg M, Wang P.
    Lipids Health Dis; 2016 Mar 12; 15():55. PubMed ID: 26968977
    [Abstract] [Full Text] [Related]

  • 11. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial.
    Raal F, Scott R, Somaratne R, Bridges I, Li G, Wasserman SM, Stein EA.
    Circulation; 2012 Nov 13; 126(20):2408-17. PubMed ID: 23129602
    [Abstract] [Full Text] [Related]

  • 12. [Heterozygous familial hypercholesterolemia: the first challenge for anti-PCSK9 monoclonal antibodies].
    Zambon A.
    G Ital Cardiol (Rome); 2016 Apr 13; 17(4 Suppl 1):22S-30. PubMed ID: 27312020
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody alirocumab vs placebo in patients with heterozygous familial hypercholesterolemia.
    Kastelein JJ, Hovingh GK, Langslet G, Baccara-Dinet MT, Gipe DA, Chaudhari U, Zhao J, Minini P, Farnier M.
    J Clin Lipidol; 2017 Apr 13; 11(1):195-203.e4. PubMed ID: 28391886
    [Abstract] [Full Text] [Related]

  • 14. Real-life LDL-C treatment goals achievement in patients with heterozygous familial hypercholesterolemia in the Czech Republic and Slovakia: Results of the PLANET registry.
    Vrablik M, Raslová K, Vohnout B, Blaha V, Satny M, Kyselak O, Vaclova M, Urbanek R, Maskova J, Soska V, Freiberger T.
    Atherosclerosis; 2018 Oct 13; 277():355-361. PubMed ID: 30270071
    [Abstract] [Full Text] [Related]

  • 15. Familial hypercholesterolemia treatments: Guidelines and new therapies.
    Raal FJ, Hovingh GK, Catapano AL.
    Atherosclerosis; 2018 Oct 13; 277():483-492. PubMed ID: 30270089
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and Safety of Alirocumab in High-Risk Patients With Clinical Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from 5 Placebo-Controlled ODYSSEY Trials).
    McCullough PA, Ballantyne CM, Sanganalmath SK, Langslet G, Baum SJ, Shah PK, Koren A, Mandel J, Davidson MH.
    Am J Cardiol; 2018 Apr 15; 121(8):940-948. PubMed ID: 29472008
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg/dl or Higher.
    Ginsberg HN, Rader DJ, Raal FJ, Guyton JR, Baccara-Dinet MT, Lorenzato C, Pordy R, Stroes E.
    Cardiovasc Drugs Ther; 2016 Oct 15; 30(5):473-483. PubMed ID: 27618825
    [Abstract] [Full Text] [Related]

  • 18. High burden of recurrent cardiovascular events in heterozygous familial hypercholesterolemia: The French Familial Hypercholesterolemia Registry.
    Béliard S, Boccara F, Cariou B, Carrié A, Collet X, Farnier M, Ferrières J, Krempf M, Peretti N, Rabès JP, Varret M, Vimont A, Charrière S, Bruckert E, French FH Registry group.
    Atherosclerosis; 2018 Oct 15; 277():334-340. PubMed ID: 30270068
    [Abstract] [Full Text] [Related]

  • 19. The efficacy of anti-PCSK9 antibodies: Results from recent trials.
    Gouni-Berthold I.
    Atheroscler Suppl; 2017 Nov 15; 30():9-18. PubMed ID: 29096867
    [Abstract] [Full Text] [Related]

  • 20. PCSK9 inhibitors in clinical practice: Delivering on the promise?
    Stoekenbroek RM, Hartgers ML, Rutte R, de Wijer DD, Stroes ESG, Hovingh GK.
    Atherosclerosis; 2018 Mar 15; 270():205-210. PubMed ID: 29254691
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.